Jak 1-3 Inhibitors and Tyk-2 Inhibitors in Dermatology: Practical Pearls for the Primary Care Physician

This review provides primary care physicians with updated information on monitoring and safety guidelines for Janus kinase (JAK) and tyrosine kinase 2 (TYK-2) inhibitors, which are FDA-approved for treating inflammatory skin conditions like atopic dermatitis, plaque psoriasis, alopecia areata, and vitiligo. These medications, while effective, require careful monitoring due to associated box warnings, emphasizing the need for primary care physicians to stay informed as these treatments become more common. The review highlights the importance of understanding the safety profiles and monitoring requirements as more therapies from these classes gain approval.